GlassScriptPhysician profile
Tracy L Markwell
NPI 1871827188
$2,224.08
in general payments reported to CMS, 2019-2025
16 companies · $641 in 2025
The $641 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $97.79 · 2023: $1,027 · 2024: $347 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,414.65 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $600.00 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $164.09 | 2023-2025 | Jynarque, Rexulti |
| Phathom Pharmaceuticals, INC. | $143.75 | 2024 | Voquezna |
| Heartflow, INC. | $132.98 | 2025 | |
| Hologic Sales and Service, LLC | $129.15 | 2025 | Aptima |
| Kyowa Kirin, INC. | $128.27 | 2024 | Crysvita |
| Viatris Specialty LLC | $124.65 | 2025 | Yupelri |
| Mylan Specialty L.P. | $122.70 | 2023 | Yupelri |
| Viiv Healthcare Company | $111.17 | 2023 | Apretude |
| Gilead Sciences, INC. | $97.79 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $97.16 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $96.51 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.22 | 2023 | Jardiance |
| Neurocrine Biosciences, INC. | $75.00 | 2024 | Ingrezza |
| Acadia Pharmaceuticals INC | $61.82 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $49.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Markwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.